Wnt pathway is affected by endocrine therapy in breast carcinomas

Basic and Applied Pathology

Volumn 4, Issue 2, 2011, Pages 38-45

  Joo, Yong Kyun ^a   Logullo, Angela Flávia ^b   Mattar, André ^a   Nonogaki, Suely ^c   Soares, Fernando Augusto ^c   Gebrim, Luíz Henrique ^a  

^a Gynecology   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Med Res Center Hospital do Cancer   (Brazil)

Author keywords

Anastrozole; Breast neoplasms; Tamoxifen; Wnt proteins

Indexed keywords

EID: 79958817159     PISSN: None     EISSN: 17559294     Source Type: Journal    
DOI: 10.1111/j.1755-9294.2011.01101.x     Document Type: Article

References (44)

1. Marchiò C, Reis-Filho JS. Molecular diagnosis in breast cancer. Diagn Pathol 2008; 14: 202-13.
2. Perou CM, Sørlie T, Eisen MB et al Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
3. Sørlie T, Perou CM, Tibshirani R et al Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
4. Rouzier R, Perou CM, Symmans WF et al Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85.
5. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
6. Cheung KL. Endocrine therapy for breast cancer: an overview. Breast 2007; 16: 327-43.
7. Swain SM. Aromatase inhibitors: a triumph of translational oncology. N Engl J Med 2005; 353: 2807-9.
8. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009: CD003370.
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
10. Patel RR, Sharma CG, Jordan VC. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 2007; 14: 113-22.
11. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-43.
12. Aguilera O, Muñoz A, Esteller M, Fraga MF. Epigenetic alterations of the Wnt/beta-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 13-21.
13. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007; 9: R63.
14. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004; 3: 36-41.
15. Jin Z, Tamura G, Tsuchiya T et al Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001; 85: 69-73.
16. Kashiwaba M, Tamura G, Ishida M. Aberrations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol 1994; 120: 727-31.
17. Sarrió D, Moreno-Bueno G, Hardisson D et al Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106: 208-15.
18. Ayyanan A, Civenni G, Ciarloni L et al Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A 2006; 103: 3799-804.
19. Lin SY, Xia W, Wang JC et al Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000; 97: 4262-6.
20. Veeck J, Niederacher D, An H et al Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006; 25: 3479-88.
21. Furuuchi K, Tada M, Yamada H et al Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 2000; 156: 1997-2005.
22. Mastroianni M, Kim S, Kim YC, Esch A, Wagner C, Alexander CM. Wnt signaling can substitute for estrogen to induce division of ERalpha-positive cells in a mouse mammary tumor model. Cancer Lett 2010; 289: 23-31.
23. Zhang X, Podsypanina K, Huang S et al Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 2005; 24: 4220-31.
24. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005; 12(Suppl 1): S47-59.
25. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2006; 97: 261-74.
26. Bosco EE, Wang Y, Xu H et al The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117: 218-28.
27. Musgrove EA, Sergio CM, Loi S et al Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 2008; 3: e2987.
28. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006: CD004272.
29. Abrial C, Mouret-Reynier MA, Curé H et al Neoadjuvant endocrine therapy in breast cancer. Breast 2006; 15: 9-19.
30. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
31. Santen RJ, Allred DC, Ardoin SP et al Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95(7 Suppl 1): s1-66.
32. Hayes DF. Markers of endocrine sensitivity. Breast Cancer Res 2008; 10(Suppl 4): S18.
33. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: R217-22.
34. Zagouri F, Sergentanis TN, Zografos GC. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol 2007; 5: 57.
35. Prasad CP, Mirza S, Sharma G et al Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008; 83: 318-25.
36. Cheng CW, Wu PE, Yu JC et al Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 2001; 20: 3814-23.
37. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387-98.
38. Gaspar C, Franken P, Molenaar L et al A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet 2009; 5: e1000547.
39. Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008; 3: 59-63.
40. Cowling VH, Cole MD. Turning the tables: Myc activates Wnt in breast cancer. Cell Cycle 2007; 6: 2625-7.
41. Mazzini RC, Elias S, Nazário AC, Kemp C, Logullo AF. Prevalence of c-myc expression in breast lesions associated with microcalcifications detected by routine mammography. Sao Paulo Med J 2009; 127: 66-70.
42. Estevão RA, Baracat EC, Logullo AF, Oshima CT, Nazário AC. Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial. Sao Paulo Med J 2007; 125: 343-50.
43. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998; 12: 3488-98.
44. Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003; 86: 295-9.